Go Pro
→ Buy These Stocks Before August 31st (From TradeSmith) (Ad)tc pixel Free OTLK Stock Alerts

Oncobiologics (OTLK) News Today

Oncobiologics logo
$0.65 -0.03 (-4.30%)
As of 08/21/2026 04:00 PM Eastern
Compare

Oncobiologics Latest News

Analysts Offer Predictions for Oncobiologics Q1 Earnings
August 22 at 2:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30975782
Analysts Issue Forecasts for Oncobiologics FY2026 Earnings
August 21 at 7:57 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analysts-issue-forecasts-for-oncobiologics-fy2026-earnings-2026-08-21/
Brookline Capital Markets Comments on Oncobiologics Q1 Earnings
August 20 at 7:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/brookline-capital-markets-comments-on-oncobiologics-q1-earnings-2026-08-20/
Short Interest in Oncobiologics, Inc. (NASDAQ:OTLK) Grows By 78.0%
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-oncobiologics-inc-nasdaqotlk-grows-by-780-2026-08-17/
Oncobiologics' (OTLK) "Buy" Rating Reiterated at BTIG Research
August 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30965452
Ghiath Sukhtian Purchases 2,525,252 Shares of Oncobiologics (NASDAQ:OTLK) Stock
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30964803
Insider Buying: Oncobiologics (NASDAQ:OTLK) Director Acquires $2,499,999.48 in Stock
August 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-otlk-insider-buying-and-selling-2026-08-15/
Oncobiologics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Hold" by Analysts
August 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30962013
Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Rating of "Hold" by Brokerages
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-inc-nasdaqotlk-given-average-rating-of-hold-by-brokerages-2026-08-15/
Oncobiologics (NASDAQ:OTLK) Downgraded by Wall Street Zen to Sell
August 15, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30961505
Oncobiologics (NASDAQ:OTLK) Downgraded to "Sell" Rating by Wall Street Zen
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-downgraded-to-sell-rating-by-wall-street-zen-2026-08-15/
Oncobiologics (NASDAQ:OTLK) Director Ghiath Sukhtian Buys 2,525,252 Shares of Stock
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-director-ghiath-sukhtian-buys-2525252-shares-of-stock-2026-08-14/
Oncobiologics (NASDAQ:OTLK) Releases Earnings Results
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-releases-earnings-results-2026-08-14/
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936801-outlook-therapeutics-inc-otlk-q3-2026-earnings-call-transcript
Oncobiologics' (OTLK) Buy Rating Reaffirmed at BTIG Research
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-otlk-buy-rating-reaffirmed-at-btig-research-2026-08-14/
Oncobiologics Q3 Earnings Call Highlights
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-q3-earnings-call-highlights-2026-08-14/
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345250/0/en/outlook-therapeutics-reports-third-quarter-fiscal-year-2026-financial-results-and-provides-business-update-highlighting-fda-approval-of-lytenava.html
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
August 14, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/price-target/26/08/61200760/outlook-therapeutics-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts?utm_source=snapi
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344189/0/en/outlook-therapeutics-announces-pricing-of-55-0-million-public-offering-of-common-stock-and-warrants.html
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340307/0/en/outlook-therapeutics-to-report-third-quarter-fiscal-year-2026-financial-results-and-host-a-corporate-update-conference-call-and-webcast-on-august-14-2026.html
Oncobiologics (OTLK) Expected to Announce Quarterly Earnings on Thursday
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-otlk-expected-to-announce-quarterly-earnings-on-thursday-2026-08-06/
Oncobiologics (NASDAQ:OTLK) Upgraded by Wall Street Zen to "Hold" Rating
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-upgraded-by-wall-street-zen-to-hold-rating-2026-08-01/
Insider Buying: Oncobiologics (NASDAQ:OTLK) Director Purchases $100,167.90 in Stock
July 30, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-otlk-insider-buying-and-selling-2026-07-30/
Faisal Ghiath Sukhtian Purchases 95,398 Shares of Oncobiologics (NASDAQ:OTLK) Stock
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/faisal-ghiath-sukhtian-purchases-95398-shares-of-oncobiologics-nasdaqotlk-stock-2026-07-29/
Oncobiologics Q3 EPS Estimate Increased by HC Wainwright
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-q3-eps-estimate-increased-by-hc-wainwright-2026-07-29/
Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs
July 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4926451-outlook-hold-caution-on-lytenava-fda-approval-and-cash-needs
Investors Purchase High Volume of Call Options on Oncobiologics (NASDAQ:OTLK)
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/investors-purchase-high-volume-of-call-options-on-oncobiologics-nasdaqotlk-2026-07-27/
Oncobiologics (NASDAQ:OTLK) Stock Price Expected to Rise, HC Wainwright Analyst Says
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-stock-price-expected-to-rise-hc-wainwright-analyst-says-2026-07-27/
Oncobiologics (NASDAQ:OTLK) Upgraded to Buy at BTIG Research
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/oncobiologics-nasdaqotlk-upgraded-to-buy-at-btig-research-2026-07-27/
US FDA approves Outlook Therapeutics' eye disease drug
July 24, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/us-fda-approves-outlook-therapeutics-eye-disease-drug-2026-07-24/
Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time
June 17, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/06/53247075/outlook-therapeutics-eye-drug-review-returns-to-fda
Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity
June 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4912616-outlook-therapeutics-potential-catalysts-offering-an-arbitrage-opportunity
Yezan Munther Haddadin Purchases 29,000 Shares of Oncobiologics (NASDAQ:OTLK) Stock
June 4, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-otlk-insider-buying-and-selling-2026-06-04/
Oncobiologics (NASDAQ:OTLK) Director Buys $5,038,428.31 in Stock
June 2, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-otlk-insider-buying-and-selling-2026-06-02/
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304397/0/en/outlook-therapeutics-announces-resubmission-of-biologics-license-application-to-u-s-fda-for-ons-5010-lytenava-bevacizumab-vikg.html
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3303231/0/en/outlook-therapeutics-announces-pricing-of-5-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules.html
Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA
May 26, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/05/52775680/outlook-shares-jump-following-fda-appeal-decision-for-lytenava?utm_source=snapi
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
May 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3300933/0/en/outlook-therapeutics-wins-appeal-following-formal-dispute-resolution-process-for-ons-5010-lytenava-bevacizumab-vikg.html
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
May 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/15/3296119/0/en/outlook-therapeutics-reports-second-quarter-fiscal-year-2026-financial-results-and-provides-corporate-update.html
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
April 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/23/3280365/0/en/outlook-therapeutics-announces-closing-of-5-0-million-registered-direct-offering.html
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3278965/0/en/outlook-therapeutics-announces-5-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules.html
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVAâ„¢ (bevacizumab-vikg)
April 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/21/3278066/0/en/Outlook-Therapeutics-Completes-Federal-Dispute-Resolution-FDR-Meeting-with-FDA-for-ONS-5010-LYTENAVA-bevacizumab-vikg.html
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
April 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/07/3269178/0/en/outlook-therapeutics-announces-formal-dispute-resolution-request-for-ons-5010-lytenava-bevacizumab-vikg-accepted-by-fda.html
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
March 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/25/3262571/0/en/outlook-therapeutics-announces-closing-of-5-0-million-public-offering.html
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
March 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/24/3261063/0/en/outlook-therapeutics-announces-pricing-of-5-0-million-public-offering.html
Outlook Therapeutics Announces Proposed Public Offering
March 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/23/3260887/0/en/outlook-therapeutics-announces-proposed-public-offering.html
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
March 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/16/3256238/0/en/outlook-therapeutics-announces-new-18-4-million-non-convertible-note-financing-and-amendment-to-existing-convertible-note.html
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
March 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/05/3250685/0/en/outlook-therapeutics-provides-update-following-type-a-meeting-with-fda-regarding-ons-5010-lytenava-bevacizumab-vikg.html
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
February 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/19/3241195/0/en/outlook-therapeutics-expands-european-footprint-with-exclusive-commercial-distribution-agreement-with-mediconsult-ag-for-lytenava-bevacizumab-gamma-in-switzerland.html
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
February 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/17/3239236/0/en/Outlook-Therapeutics-Reports-First-Quarter-Fiscal-Year-2026-Financial-Results-and-Provides-Corporate-Update.html

Oncobiologics Media Mentions By Week

Oncobiologics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OTLK
News Sentiment
▼
1.01

0.62
▲
Average
Healthcare
News Sentiment

Oncobiologics News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OTLK Articles
This Week
▼
13

3
▲
OTLK Articles
Average Week

Oncobiologics Trends on MarketBeat

This week vs. last week
New Followers
2
+100%
Searches
6
-40%
Page Views
3,145
-8%
Get Oncobiologics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools

Related Companies
News and Trends Tools

This page (NASDAQ:OTLK) was last updated on 8/22/2026 by MarketBeat.com Staff.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel